Antifibrotic activity of an inhibitor of histone deacetylases in DOCA-salt hypertensive rats
about
Dysregulation of histone acetyltransferases and deacetylases in cardiovascular diseasesSignaling effectors underlying pathologic growth and remodeling of the heartTherapeutic efficacy of valproic acid in a combined monocrotaline and chronic hypoxia rat model of severe pulmonary hypertensionPharmacological inhibition of soluble epoxide hydrolase ameliorates diet-induced metabolic syndrome in ratsHDAC class I inhibitor, Mocetinostat, reverses cardiac fibrosis in heart failure and diminishes CD90+ cardiac myofibroblast activationMicroRNA-124 controls the proliferative, migratory, and inflammatory phenotype of pulmonary vascular fibroblastsTargeting inflammation in heart failure with histone deacetylase inhibitors.Cardiac HDAC6 catalytic activity is induced in response to chronic hypertensionEmergence of fibroblasts with a proinflammatory epigenetically altered phenotype in severe hypoxic pulmonary hypertensionRoles and post-translational regulation of cardiac class IIa histone deacetylase isoforms.Inhibition of class I histone deacetylase activity represses matrix metalloproteinase-2 and -9 expression and preserves LV function postmyocardial infarction.Anti-Fibrotic Effects of Class I HDAC Inhibitor, Mocetinostat Is Associated with IL-6/Stat3 Signaling in Ischemic Heart Failure.Angiotensin II regulates brain (pro)renin receptor expression through activation of cAMP response element-binding protein.An inhibitor of phospholipase A2 group IIA modulates adipocyte signaling and protects against diet-induced metabolic syndrome in ratsHDAC inhibition attenuates cardiac hypertrophy by acetylation and deacetylation of target genes.The histone 3 lysine 9 methyltransferase inhibitor chaetocin improves prognosis in a rat model of high salt diet-induced heart failure.Effect of morin, a flavonoid against DOCA-salt hypertensive rats: a dose dependent studySynergistic induction of miR-126 by hypoxia and HDAC inhibitors in cardiac myocytes.HDAC-dependent ventricular remodeling.Epigenetic Modification Prevents Excessive Wound Healing and Scar Formation After Glaucoma Filtration Surgery.Retinoic acid and sodium butyrate suppress the cardiac expression of hypertrophic markers and proinflammatory mediators in Npr1 gene-disrupted haplotype mice.Histone deacetylase inhibitor, CG200745, attenuates cardiac hypertrophy and fibrosis in DOCA-induced hypertensive rats.The DOCA-Salt Hypertensive Rat as a Model of Cardiovascular Oxidative and Inflammatory StressLysine acetylation in obesity, diabetes and metabolic disease.Epigenetics: Concepts and relevance to IBD pathogenesis.Epigenetics within the matrix: a neo-regulator of fibrotic disease.Targeting cardiac fibroblasts to treat fibrosis of the heart: focus on HDACs.Epigenetic Therapy for the Treatment of Hypertension-Induced Cardiac Hypertrophy and Fibrosis.Role of epigenetics in modulation of immune response at the junction of host-pathogen interaction and danger molecule signaling.Epigenetics in Reactive and Reparative Cardiac Fibrogenesis: The Promise of Epigenetic Therapy.SAHA Suppresses Peritoneal Fibrosis in Mice.Lysine acetyltransferases cyclic adenosine monophosphate response element-binding binding protein and acetyltransferase p300 attenuate transcriptional activity of the mineralocorticoid receptor through its acetylation.Inhibitors of Histone Deacetylases Attenuate Noise-Induced Hearing Loss.Targeting the adventitial microenvironment in pulmonary hypertension: A potential approach to therapy that considers epigenetic change.Histone deacetylase inhibition, but not a mineralocorticoid receptor antagonist spironolactone, attenuates atypical transcription by an activating mutant MR (MRS 810L ).Lysine deacetylase inhibition attenuates hypertension and is accompanied by acetylation of mineralocorticoid receptor instead of histone acetylation in spontaneously hypertensive rats.Differential Anti-inflammatory Activity of HDAC Inhibitors in Human Macrophages and Rat ArthritisEpigenetics in Cardiac Fibrosis: Emphasis on Inflammation and Fibroblast ActivationThe Crosstalk between Acetylation and Phosphorylation: Emerging New Roles for HDAC Inhibitors in the Heart
P2860
Q21284678-75451E70-1722-44A3-89CE-B916DA85FBF1Q26825154-F652CF6A-284F-474C-B208-3802D703DAFBQ27316522-AF23C7AE-C925-4062-B0AB-CC97EB04AB86Q28392609-4012C341-DEE6-499D-9E62-51DFD115C66BQ33891516-5938A76F-8649-4F72-9AEC-52988FB9E9CDQ33982509-84FE21AE-471B-47C6-87AC-2FC411ADE08AQ35016989-F6AE8FB1-6787-42C4-8EA2-0F6F3693387AQ35040811-841371DD-57BA-4108-8370-776BDBBAF484Q35175427-258FA705-05BE-42C2-9536-AD4F8F9722ECQ35517710-0FBA4D43-B0D4-453A-9C67-C2CAD7453CBAQ35671740-22C1CB61-6A4A-45DA-A1BE-6CD2384A2D81Q35723859-F8DBC43D-EB90-4A94-B86F-26D069F7448AQ35859268-D5AAAB0C-288E-46FE-9773-7EA246B1A9C0Q36182494-DEBBB8A4-2472-4BF0-A651-4E5714D075E0Q36212830-3B666FD5-173F-46B5-B4F9-A2D640584E03Q36239248-4C9A14B1-E285-48F0-9D16-CD999BA820FAQ36719779-F4CC7317-11FB-47E4-BDAE-45D3BF4CE0A2Q36800026-955D99F8-6076-4C4C-A235-7FA77666FF56Q36945016-8C118C60-AEA4-4C2D-A328-909C9B672BBFQ37126439-A5EA88D3-4030-42CA-A165-F5B6E9137EE8Q37139674-8E711BAE-5047-4CEB-B6B2-DEFE92313435Q37239770-BFFAFBAA-DA46-4778-8152-E014576A5D7EQ37951441-2784A4B1-9E9A-4132-9604-4D4EB0985690Q37956175-B4EE1C7F-24AA-411F-86DC-68BA89E33CB0Q37992592-CDEFC4B9-C2AB-4C95-A6CB-0F24AD362842Q38034837-F2A9C775-801F-4025-9138-5C62F0B0A209Q38196176-C94AF200-E64C-40E1-A3AE-7DDE2F0CA57FQ38858284-B796C3AC-0293-49D7-A6ED-410B06938D26Q38932108-D4656864-02D0-43F2-AC93-C7C77CD6CADEQ39018712-A07BCB78-DB35-4530-A327-2FB3F2C64445Q41083786-7017DE36-6E63-4F1E-88D4-ECBD868868A0Q41364734-606D5C4B-CE1F-4C64-A7E0-C781DE39716DQ41827137-A4A31A36-6D47-4466-9527-7697585460A3Q42145272-D0455BBB-E795-4612-9509-C020CFB5D74BQ47866992-65E8E244-1887-4C07-BFB6-A5F985E8E976Q51464359-BFD3B32A-B4F1-4F9F-A5AF-C62D9F3EEC39Q57080797-FC86B280-5CD8-4B00-A609-9D528521D04AQ59136748-732A2EEF-2E09-4D53-A7AA-034E92D4E897Q60927794-ba06c4cd-428f-09ab-93b0-6e4f79cfcc64
P2860
Antifibrotic activity of an inhibitor of histone deacetylases in DOCA-salt hypertensive rats
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Antifibrotic activity of an in ...... in DOCA-salt hypertensive rats
@ast
Antifibrotic activity of an in ...... in DOCA-salt hypertensive rats
@en
type
label
Antifibrotic activity of an in ...... in DOCA-salt hypertensive rats
@ast
Antifibrotic activity of an in ...... in DOCA-salt hypertensive rats
@en
prefLabel
Antifibrotic activity of an in ...... in DOCA-salt hypertensive rats
@ast
Antifibrotic activity of an in ...... in DOCA-salt hypertensive rats
@en
P2093
P2860
P50
P1476
Antifibrotic activity of an in ...... in DOCA-salt hypertensive rats
@en
P2093
Andrew Fenning
Giang T Le
Lindsay Brown
Maria A Halili
P2860
P304
P356
10.1111/J.1476-5381.2010.00637.X
P407
P577
2010-02-24T00:00:00Z